Teva Pharmaceutical Industries Limited (NYSE: TEVA) is considered one of the best healthcare stocks to buy for 2026. Truist Securities raised its price target on Teva Pharma to $38 from $36 following Q4 2025 results with a $500 million milestone payment. Despite revenue missing estimates, Teva’s growth story remains intact, with potential FDA decisions on Olanzapine LAI in 2026 unlocking a $3B sales opportunity.

Teva Pharmaceutical Industries reported strong Q4 2025 results, beating expectations with EPS of $0.96 and revenue of $4.71 billion, aided by a $500 million milestone payment from Sanofi. However, shares slipped as Teva projected lower 2026 revenue of $16.4–$16.8 billion due to lost sales of generic Revlimid. The company’s innovative portfolio, including Austedo, Ajovy, and Uzedy, is expected to drive growth in 2026.

Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, focusing on central nervous system, respiratory, and oncology treatments. Despite near-term headwinds affecting guidance, the company is transitioning from a generics-focused firm to a biopharma player, with core earnings projected to rise supported by expanding branded medicines and pipeline momentum.

Read more at Yahoo Finance: Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds